Home » Clinical Trials » Solid tumors » NCT04467853
NCT04467853

A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors

Study Summary

This is a prospective, single-arm, open-label Phase 1 dose-finding and expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the cell-based LCAR-C18S (hereinafter "LCAR-C18S") in subjects with Claudin18.2-positive advanced solid Tumors.

Want to learn more about this trial?

Request More Info

Interventions

LCAR-C18S cellsBIOLOGICAL
Before treatment with LCAR-C18S cells, subjects will receive a conditioning regimen

Study Locations

FacilityCityStateCountry
Anhui Provincial HospitalHefeiAnhuiChina
Shanghai East HospitalShanghaiChina/ShanghaiChina
Shanghai Artemed HospitalShanghaiShanghai MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026